BioMarin Pharmaceutical Inc. ( BMRN ) NASDAQ Global Select

Cena: 59.56 ( 0.61% )

Aktualizacja 07-23 16:18
NASDAQ Global Select
Branża: Biotechnology

Notowania:


Informacje o spółce:
Sektor: Zdrowie
Branża: Biotechnology
Zatrudnienie: 3 401
Giełda: NASDAQ Global Select
Ilość akcji w obrocie: 98.0544
Ilość akcji: Brak danych
Debiut giełdowy: 1999-07-26
WWW: https://www.biomarin.com
CEO: Mr. Alexander Hardy
Adres: 770 Lindaro Street
Siedziba: 94901 San Rafael
ISIN: US09061G1013
Opis firmy:

Biomarin Pharmaceutical Inc. opracowuje i komercjalizuje terapie u osób z poważnymi i zagrażającymi życiu rzadkimi chorobami i chorobami. Jego produkty komercyjne obejmują Vimizim, enzymową terapię zastępczą w leczeniu mukopolisacharydozy (MPS) IV typu A, zaburzenia magazynowania lizosomalnego; Naglazyme, rekombinowana postać 4-sulfatazy N-acetylgalaktozoaminy u pacjentów z MPS VI; i Kuvan, zastrzeżona syntetyczna doustna postać 6R-BH4, która jest stosowana w leczeniu pacjentów z fenyloketonurią (PKU), dziedzicznej choroby metabolicznej. Produkty komercyjne firmy obejmują również Palynziq, enzym liazy fenyloalaniny amoniaku fenyloalaniny, który jest dostarczany przez wstrzyknięcie podskórne w celu zmniejszenia stężenia Phe we krwi; Bryineura, rekombinowana ludzka peptydaza tripeptydylowa 1 w leczeniu pacjentów z ceidyczną lipofuscynozą typu 2, postać choroby Batten; Voxzogo, niegdyś dzienny analog iniekcyjny peptydu natriuretycznego typu C do leczenia achondroplazji; i aldurazym, oczyszczone białko zaprojektowane tak, aby było identyczne z naturalnie występującą postacią ludzkiego enzymu alfa-L-iduronidazy. Ponadto opracowuje Valoktokogen Roxaparvovec, wektor wirusa związanego z adeno, który jest w badaniu klinicznym fazy III w leczeniu pacjentów z ciężką hemofilią A; BMN 307, terapia genowa za pośrednictwem AAV5, która znajduje się w badaniu klinicznym fazy 1/2 w celu normalizacji poziomów stężenia Phe we krwi u pacjentów z PKU; i BMN 255, które jest w badaniu klinicznym fazy 1/2 w leczeniu pierwotnej hiperoksalurii. Firma obsługuje apteki specjalistyczne, szpitale i agencje rządowe spoza USA, a także dystrybutorów i hurtowników farmaceutycznych w Stanach Zjednoczonych, Europie, Ameryce Łacińskiej i na arenie międzynarodowej. Biomarin Pharmaceutical Inc. ma umowy licencyjne i współpracujące z Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. i Asubio Pharma Co., Ltd. Firma została zarejestrowana w 1996 roku i ma siedzibę w San Rafael w Kalifornii.

Wskaźniki finansowe
Kapitalizacja (USD) 11 422 178 560
Aktywa: 6 851 195 000
Cena: 59.56
Wskaźnik Altman Z-Score: 6.3
Stabilny (niskie ryzyko bankructwa)
Dywidenda: 0
P/E: 22.1
Ilość akcji w obrocie: 98%
Średni wolumen: 2 029 950
Ilość akcji 191 776 000
Wskaźniki finansowe
Przychody TTM 2 749 438 000
Zobowiązania: 1 437 799 000
Przedział 52 tyg.: 52.93 - 94.85
Piotroski F-Score: 6
Umiarkowany (średnia jakość finansowa)
EPS: 2.7
P/E branży: 26.1
Beta: 0.31
Raport okresowy: 2025-08-04
WWW: https://www.biomarin.com
Zarząd
Imie i Nazwisko Stanowisko Wynagrodzenie Rok urodzenia
Mr. Alexander Hardy President, Chief Executive Officer & Director 1 715 598 1969
Dr. Henry J. Fuchs M.D., Ph.D. President of Worldwide Research & Development 1 411 725 1958
Mr. George Eric Davis Executive Vice President, Chief Legal Officer, General Counsel & Secretary 1 231 702 1971
Dr. C. Greg Guyer Ph.D. Executive Vice President & Chief Technology Officer 1 114 215 1962
Mr. Brian R. Mueller Chief Financial Officer & Executive Vice President 1 074 819 1974
Ms. Amy Wireman Executive Vice President & Chief People Officer 0 0
Ms. Erin Burkhart Group Vice President & Chief Accounting Officer 0 1979
Dr. Kevin Eggan Ph.D. Chief Scientific Officer & Senior Vice President of Research and Early Development 0 0
Traci McCarty Group Vice President of Investor Relations 0 0
Ms. Humaira Serajuddin Senior Vice President & Chief Marketing Officer 0 0
Lista ETF z ekspozycją na akcje BioMarin Pharmaceutical Inc.
Symbol ETF Ilość akcji Wartość
IJH 6 259 940 359 383 165
VB 4 812 098 279 438 530
VBK 2 647 735 153 753 971
XBI 2 036 751 120 787 523
MDY 1 480 555 85 190 419
IBB 1 180 151 67 752 480
IJJ 1 067 851 61 305 350
SPMD 872 820 50 176 544
USMV 832 073 47 844 197
IWR 664 322 38 138 715
VHT 599 630 34 820 514
FBT 551 701 31 673 154
SCHM 508 476 29 237 370
IWD 425 255 24 413 867
MDYV 330 293 19 096 000
SCHG 291 979 16 782 582
FXH 291 971 16 762 055
IWDA.AS 287 447 16 502 327
SWDA.L 287 447 16 502 327
IWDG.L 287 447 16 502 327
IWLE.DE 287 447 16 502 327
IWDA.L 287 447 16 502 327
SWDA.MI 287 447 16 502 327
IWDD.AS 287 447 16 502 327
EUNL.DE 287 447 16 502 327
IVOO 283 505 16 463 135
IWS 277 010 15 903 120
SCHX 189 839 10 915 742
FNDA 188 767 10 338 647
PBE 187 256 10 767 220
LABU 171 822 9 823 063
IUSV 153 037 8 785 827
IVOV 140 570 8 162 899
IWB 134 702 7 733 232
WMVG.L 114 846 6 593 295
MVSH.SW 114 846 6 593 295
SXR0.DE 114 846 6 593 295
MINV.L 114 846 6 593 295
IQQ0.DE 114 846 6 593 295
UEEH.DE 114 846 6 593 295
MVOL.L 114 846 6 593 295
2B70.DE 113 918 6 540 050
BTEE.L 113 918 6 540 050
BTEK.L 113 918 6 540 050
BTEC.L 113 918 6 540 050
IYH 102 347 5 875 752
SP5H.PA 101 644 6 065 097
ETFSP500.WA 101 644 6 065 097
SP5L.L 101 644 6 065 097
LSPX.L 101 644 6 065 097
LYP2.DE 101 644 6 065 097
LSPU.L 101 644 6 065 097
6TVM.DE 101 644 6 065 097
VONV 101 622 5 901 189
BBH 91 728 5 244 089
VGWL.DE 88 030 4 353 807
VWRP.L 88 030 3 761 081
VWCE.DE 88 030 4 353 807
VWRL.AS 88 030 4 353 807
VWRL.L 88 030 3 761 081
VWRD.L 88 030 5 111 902
FHLC 82 380 4 709 664
ACWV 81 662 4 695 565
JHMM 75 269 4 619 258
QQQJ 72 052 4 142 990
IMCG 65 459 3 758 027
ISAC.L 57 338 3 291 760
SSAC.L 57 338 3 291 760
IUSQ.DE 57 338 3 291 760
SLUS.DE 56 949 3 269 450
SGAS.DE 56 949 3 269 450
SAUA.MI 56 949 3 269 450
SASU.L 56 949 3 269 450
GPSA.L 56 949 3 269 450
SDUS.L 56 949 3 269 450
ACWI 49 931 2 866 547
IWV 49 558 2 845 100
ONEQ 45 261 2 602 507
EUSA 45 144 2 591 697
ESGV 40 941 2 894 119
SPTM 35 538 2 040 195
SFLO 33 849 1 946 317
OM3L.DE 31 687 1 819 127
EDMU.DE 31 687 1 819 127
EEDG.L 31 687 1 819 127
EDMU.SW 31 687 1 819 127
EEDS.L 31 687 1 819 127
CBUC.DE 31 687 1 819 127
VONE 29 000 1 684 030
PBUS 28 895 1 661 462
PTMC 28 100 1 615 750
GNOM 26 777 1 597 783
AVUS 26 749 1 538 067
FNX 26 010 1 493 234
QVMM 25 547 1 468 952
XMC.TO 24 974 1 956 213
PRF 23 113 1 328 997
FNY 21 738 1 247 978
VEVE.L 21 196 905 599
VHVE.L 21 196 1 230 851
VDEV.L 21 196 1 230 851
VGVE.DE 21 196 1 048 316
VGVF.DE 21 196 1 048 316
XJH 20 824 1 197 380
IJH.AX 19 643 1 731 102
TNOW.L 19 640 1 171 918
LYPG.DE 19 640 1 171 918
LYTNOW.SW 19 640 1 171 918
QUS 19 609 1 125 136
USMF 19 062 1 042 500
EZM 18 713 1 052 044
IMCB 18 267 1 048 685
BBUS 17 698 972 859
RWK 17 253 992 047
HTEC 17 051 0
PABU 16 988 975 281
QDVC.DE 16 842 966 920
IUSF.L 16 842 966 920
IUSZ.L 16 842 966 920
XMH.TO 16 458 1 289 191
SAWD.L 15 335 880 382
S6DW.DE 15 335 880 382
SNAW.DE 15 335 880 382
SDWD.L 15 335 880 382
VTHR 14 843 861 933
ONEV 14 784 852 870
VNRA.DE 14 430 713 682
VNRT.L 14 430 616 521
VDNR.L 14 430 837 950
VNRA.L 14 430 837 950
VNRG.L 14 430 616 521
VNRT.DE 14 430 713 682
SCHK 14 328 787 610
ILCG 12 939 742 842
URTH 12 256 703 627
CFA 11 676 671 370
USXF 11 127 638 825
SIZE 10 790 619 447
SDG 10 771 618 355
IWDE.L 10 249 588 400
IBCH.DE 10 249 588 400
EQAL 10 222 587 765
RECS 10 199 586 442
XMU.TO 9 723 761 576
GDOC 9 685 556 887
XUU.TO 9 586 1 073 103
CFO 9 226 530 495
XEQT.TO 8 575 671 708
VFMV 8 370 591 675
ISWD.L 8 351 479 435
ISWD.SW 8 351 479 435
ISDW.L 8 351 479 435
IYY 8 097 464 830
KOMP 7 959 455 960
IBBQ 7 896 454 020
BBP 7 758 426 690
MVV 7 564 434 930
BIB 7 066 406 295
CSUS.L 6 781 389 275
CU1.L 6 781 389 275
SXR4.DE 6 781 389 275
CSUS.SW 6 781 389 275
IMCV 6 672 383 065
IS3T.DE 6 491 372 657
IWFS.L 6 491 372 657
IWSZ.L 6 491 372 657
GUSA 6 406 368 345
JHML 5 936 364 292
FAD 5 724 328 614
PEXL 5 713 328 497
XAW.TO 5 274 413 092
AVMC 5 088 292 560
HLAL 4 885 329 639
DRUP 4 564 0
IQQN.DE 4 150 238 280
INAA.L 4 150 238 280
IDNA.L 4 150 238 280
INAA.SW 4 150 238 280
CBUF.DE 4 118 236 440
WHCS.AS 4 118 236 440
WHCA.AS 4 118 236 440
ISDU.L 3 977 228 332
ISUS.L 3 977 228 332
TILT 3 720 221 972
EDMW.DE 3 709 212 922
EGMW.L 3 709 212 922
EEWD.L 3 709 212 922
EEWG.L 3 709 212 922
EMND.DE 3 709 212 922
ILCB 3 646 209 300
IWDC.SW 3 515 201 817
MIDU 3 494 199 751
BALI 3 474 195 308
XMW.TO 3 465 275 016
FMDE 3 322 189 918
MUSD.AS 3 301 178 716
FTXH 2 791 160 231
AVLC 2 783 160 022
V3AA.L 2 683 155 801
V3AL.L 2 683 155 801
GVUS 2 441 140 357
XUSR.TO 2 216 173 573
AVSU 2 206 126 845
ILCV 2 205 126 615
WVOL.AX 1 987 212 032
CSH2.PA 1 796 107 167
XMY.TO 1 687 132 112
QWLD 1 680 96 548
KOKU 1 631 93 782
FNDB 1 454 79 926
WINC.L 1 423 81 707
AFMC 1 392 79 914
XUH.TO 1 375 107 685
WPAD.AS 1 350 77 510
WPAB.SW 1 350 77 510
WPAB.AS 1 350 77 510
XMS.TO 1 329 104 131
XBAL.TO 1 322 108 054
R1VL.L 1 276 73 255
UMDD 1 249 71 817
FTQI 1 103 63 323
VLU 1 071 61 700
CEMG.DE 1 036 59 455
CEMG.L 1 036 59 455
STXM 976 56 120
WBIO.L 945 51 682
WDNA.L 945 51 682
VVO.TO 803 81 697
IGWD.L 758 43 496
DEUS 656 37 720
QQJG 600 34 500
STXG 581 33 407
WOMN 553 31 797
TOK 545 31 280
REVS 534 30 705
MIDE 505 29 037
GEQT.TO 481 37 715
MFUS 455 25 011
ONOF 444 26 493
WDNA 431 24 230
GGRO.TO 425 33 318
ONEO 397 22 756
NZAC 388 22 286
QARP 373 21 447
GBAL.TO 280 21 968
XMAG 167 9 602
AVIE 125 7 187
STXV 103 5 922
GCNS.TO 59 4 644
XTR.TO 57 4 507
INRO 45 2 482
NZUS 21 1 209
MMTM 19 1 089
PXS.TO 0 0
Wiadomości dla BioMarin Pharmaceutical Inc.
Tytuł Treść Źródło Aktualizacja Link
BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma Acquisition is Strong Strategic Fit for BioMarin, Adding INZ-701, a Phase 3 Enzyme Replacement Therapy Being Developed for Treatment of ENPP1 Deficiency First Pivotal Data Readout in Children Expected in Early 2026 with Potential Launch in 2027; Additional Clinical Programs to Expand to Patients of all Ages  Potential First-in-Disease Treatment for ENPP1 Deficiency Conference Call and Webcast Scheduled Today at 8:45 a.m. ET SAN RAFAEL, Calif. prnewswire.com 2025-05-16 11:30:00 Czytaj oryginał (ang.)
BioMarin Presents New Data for VOXZOGO® (vosoritide) in Children with Achondroplasia and Other Skeletal Conditions at Two International Endocrinology Meetings New data in children under 5 years with achondroplasia showed treatment with VOXZOGO was associated with improvement in tibial bowing, a common cause of pain and impaired function  Data from the largest retrospective, multi-year observational study of more than 600 children and adults with hypochondroplasia found significantly higher rates of comorbidities, surgeries and overall doctor visits  SAN RAFAEL, Calif. , May 12, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced new data from studies of VOXZOGO ® (vosoritide), demonstrating meaningful impact on tibial bowing in children with achondroplasia and investigational early efficacy results in other skeletal conditions. prnewswire.com 2025-05-12 13:05:00 Czytaj oryginał (ang.)
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. zacks.com 2025-05-09 14:40:46 Czytaj oryginał (ang.)
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. zacks.com 2025-05-06 14:50:35 Czytaj oryginał (ang.)
Why BioMarin Pharmaceutical (BMRN) is a Top Momentum Stock for the Long-Term Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. zacks.com 2025-05-05 14:55:35 Czytaj oryginał (ang.)
BioMarin's First-Quarter Earnings & Sales Beat Estimates BMRN reports encouraging first-quarter results. The company reiterates its financial guidance for 2025. zacks.com 2025-05-02 18:25:31 Czytaj oryginał (ang.)
BioMarin (BMRN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates While the top- and bottom-line numbers for BioMarin (BMRN) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. zacks.com 2025-05-02 00:35:38 Czytaj oryginał (ang.)
BioMarin Pharmaceutical Inc. (BMRN) Q1 2025 Earnings Call Transcript BioMarin Pharmaceutical Inc. (BMRN) Q1 2025 Earnings Call Transcript seekingalpha.com 2025-05-01 23:25:29 Czytaj oryginał (ang.)
BioMarin Pharmaceutical (BMRN) Beats Q1 Earnings and Revenue Estimates BioMarin Pharmaceutical (BMRN) came out with quarterly earnings of $1.13 per share, beating the Zacks Consensus Estimate of $0.94 per share. This compares to earnings of $0.71 per share a year ago. zacks.com 2025-05-01 22:20:48 Czytaj oryginał (ang.)
BioMarin Reports First Quarter 2025 Results and Reaffirms Full-year Guidance First Quarter 2025 Total Revenues of $745 million (+15% Y/Y and +17% at Constant Currency Y/Y) First Quarter 2025 GAAP Diluted Earnings Per Share (EPS) of $0.95 (+107% Y/Y) First Quarter 2025 Non-GAAP Diluted EPS of $1.13 (+59% Y/Y)  Conference Call and Webcast Scheduled Today at 4:30 p.m. ET SAN RAFAEL, Calif. prnewswire.com 2025-05-01 20:05:00 Czytaj oryginał (ang.)
Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. zacks.com 2025-04-23 14:46:21 Czytaj oryginał (ang.)
Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. zacks.com 2025-04-18 14:45:38 Czytaj oryginał (ang.)
BioMarin to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 4:30pm ET SAN RAFAEL, Calif. , April 17, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, May 1, 2025, at 4:30 p.m. prnewswire.com 2025-04-17 13:00:00 Czytaj oryginał (ang.)
BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: What to Know Ahead of Q1 Release BioMarin (BMRN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com 2025-04-16 15:06:07 Czytaj oryginał (ang.)
6 Stocks With Clear Price Dislocations That I Purchased During Wall Street's Historic Volatility The old idiom "blink, and you'll miss it" might be the best descriptor of the historic volatility we've witnessed on Wall Street over the trailing week, as of this writing on April 9. fool.com 2025-04-11 07:06:00 Czytaj oryginał (ang.)
Will BioMarin (BMRN) Beat Estimates Again in Its Next Earnings Report? BioMarin (BMRN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report. zacks.com 2025-04-10 17:15:45 Czytaj oryginał (ang.)
Strength Seen in BioMarin (BMRN): Can Its 6.3% Jump Turn into More Strength? BioMarin (BMRN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road. zacks.com 2025-04-10 13:20:41 Czytaj oryginał (ang.)
Will Trump Tariffs Make or Break Healthcare Space? 3 Stocks to Rely On Investors looking to maintain exposure to healthcare can invest in large-cap U.S.-based companies like UHS, BMRN and ABT. zacks.com 2025-04-09 20:00:41 Czytaj oryginał (ang.)
5 Biotech Stocks Worth Adding Amid Global Uncertainty in 2025 New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position GILD, BMRN, KRYS, ADMA and FOLD well in this volatile sector. zacks.com 2025-04-07 18:25:39 Czytaj oryginał (ang.)
3 Reasons Why Growth Investors Shouldn't Overlook BioMarin (BMRN) BioMarin (BMRN) possesses solid growth attributes, which could help it handily outperform the market. zacks.com 2025-04-07 17:45:33 Czytaj oryginał (ang.)
BioMarin to Present at the TD Cowen 45th Annual Healthcare Conference on Tuesday, March 4 at 6:50 AM PT / 9:50 AM ET in Boston, MA SAN RAFAEL, Calif. , Feb. 25, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will present at the TD Cowen 45th Annual Healthcare Conference on Tuesday, March 4, 2025, at 6:50 AM PT / 9:50 AM ET in Boston, MA. prnewswire.com 2025-02-25 11:00:00 Czytaj oryginał (ang.)
BioMarin Announces Appointment of Timothy P. Walbert to Board of Directors SAN RAFAEL, Calif. , Feb. 24, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the company has appointed Timothy P. prnewswire.com 2025-02-24 18:05:00 Czytaj oryginał (ang.)
BioMarin (BMRN) is an Incredible Growth Stock: 3 Reasons Why BioMarin (BMRN) possesses solid growth attributes, which could help it handily outperform the market. zacks.com 2025-02-24 15:45:34 Czytaj oryginał (ang.)
Does BioMarin (BMRN) Have the Potential to Rally 40.54% as Wall Street Analysts Expect? The average of price targets set by Wall Street analysts indicates a potential upside of 40.5% in BioMarin (BMRN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. zacks.com 2025-02-24 12:55:29 Czytaj oryginał (ang.)
Why BioMarin Pharmaceutical Stock Zoomed Almost 5% Higher Today BioMarin Pharmaceutical (BMRN 4.75%) was a lively stock in the best way on Thursday following the release of its latest set of quarterly results. Enthusiastic investors traded the company's shares up by nearly 5% in price, contrasting quite sharply with the 0.4% decline of the S&P 500 index on the day. fool.com 2025-02-20 19:56:00 Czytaj oryginał (ang.)
BioMarin Q4 Earnings & Sales Top Estimates, Stock Up on Upbeat '25 View BMRN reports better-than-expected fourth-quarter results, driven by encouraging uptake for Voxzogo. It reiterates its guidance of generating $4 billion in total sales by 2027. zacks.com 2025-02-20 12:26:19 Czytaj oryginał (ang.)
Why Is BioMarin Stock Trading Higher On Thursday? On Wednesday, BioMarin Pharmaceutical Inc.  BMRN reported fourth-quarter adjusted EPS of 92 cents, up from 49 cents reported a year ago, beating the consensus of 53 cents. benzinga.com 2025-02-20 11:39:31 Czytaj oryginał (ang.)
BioMarin Pharmaceutical Inc. (BMRN) Q4 2024 Earnings Call Transcript BioMarin Pharmaceutical Inc. (NASDAQ:BMRN ) Q4 2024 Earnings Conference Call February 19, 2025 4:30 PM ET Company Participants Traci McCarty - Head of IR Alexander Hardy - President and CEO Brian Mueller - EVP and CFO Cristin Hubbard - EVP and Chief Commercial Officer Greg Friberg - EVP and Chief Research & Development Officer Conference Call Participants Philip Nadeau - TD Cowen Jessica Fye - JPMorgan Cory Kasimov - Evercore Christopher Raymond - Piper Sandler Gena Wang - Barclays Julian Pino - Stifel Akash Tewari - Jefferies Eli Merle - UBS Kostas Biliouris - BMO Capital Markets Sadia Rahman - Wells Fargo Olivia Brayer - Cantor Fitzgerald Alex Hammond - Wolfe Research Operator Ladies and gentlemen, thank you for standing by and welcome to the BioMarin Pharmaceuticals fourth quarter and full year 2024 conference call. All lines have been placed on mute to prevent any background noise. seekingalpha.com 2025-02-19 22:08:58 Czytaj oryginał (ang.)
Compared to Estimates, BioMarin (BMRN) Q4 Earnings: A Look at Key Metrics While the top- and bottom-line numbers for BioMarin (BMRN) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. zacks.com 2025-02-19 20:31:14 Czytaj oryginał (ang.)
BioMarin Pharmaceutical (BMRN) Surpasses Q4 Earnings and Revenue Estimates BioMarin Pharmaceutical (BMRN) came out with quarterly earnings of $0.92 per share, beating the Zacks Consensus Estimate of $0.73 per share. This compares to earnings of $0.49 per share a year ago. zacks.com 2025-02-19 20:20:24 Czytaj oryginał (ang.)
BioMarin: EPS Surges Past Expectations BioMarin Pharmaceutical (BMRN 1.16%), a leader in developing innovative therapies for rare genetic disorders, reported fourth-quarter 2024 financial results on Wednesday, Feb. 19, that topped analysts' consensus expectations. Adjusted earnings per share (EPS) reached $0.92, significantly outperforming the anticipated $0.53. fool.com 2025-02-19 18:50:03 Czytaj oryginał (ang.)
BioMarin Reports Fourth Quarter and Full Year 2024 Results; Sets Full Year 2025 Guidance Strong Execution and Operational Transformation in 2024 Delivered Record Full Year Results and Provides Momentum for Double-Digit Revenue and Profitability Growth in 2025 4Q 2024 Total Revenues of $747 million (+16% Y/Y and +21% at Constant Currency Y/Y); FY 2024 Total Revenues of $2.85 billion (+18% Y/Y and +22% at Constant Currency Y/Y) Conference Call and Webcast Scheduled Today at 4:30 p.m. ET SAN RAFAEL, Calif. prnewswire.com 2025-02-19 18:05:00 Czytaj oryginał (ang.)
Will These 5 Biotech Stocks Surpass Q4 Earnings Forecast? Let's look at five biotech and drug companies, AXSM, HALO, FOLD, BMRN and INSM, slated to release their fourth-quarter 2024 results this week. zacks.com 2025-02-17 12:30:34 Czytaj oryginał (ang.)
BioMarin to Report Q4 Earnings: Here's What to Expect When BMRN reports fourth-quarter earnings, investors will likely focus on the sales performance of its dwarfism drug Voxzogo. zacks.com 2025-02-17 10:21:07 Czytaj oryginał (ang.)
Unveiling BioMarin (BMRN) Q4 Outlook: Wall Street Estimates for Key Metrics Get a deeper insight into the potential performance of BioMarin (BMRN) for the quarter ended December 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics. zacks.com 2025-02-13 12:16:16 Czytaj oryginał (ang.)
BMRN vs. CSLLY: Which Stock Is the Better Value Option? Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both BioMarin Pharmaceutical (BMRN) and CSL Limited Sponsored ADR (CSLLY). But which of these two stocks is more attractive to value investors? zacks.com 2025-02-12 14:41:17 Czytaj oryginał (ang.)
BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release BioMarin (BMRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com 2025-02-12 13:06:31 Czytaj oryginał (ang.)
3 Reasons Growth Investors Will Love BioMarin (BMRN) BioMarin (BMRN) is well positioned to outperform the market, as it exhibits above-average growth in financials. zacks.com 2025-02-05 15:45:33 Czytaj oryginał (ang.)
BioMarin to Host Fourth Quarter and Full-Year 2024 Financial Results Conference Call and Webcast on Wednesday, February 19, 2025, at 4:30pm ET SAN RAFAEL, Calif. , Feb. 5, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, February 19, 2025, at 4:30 p.m. prnewswire.com 2025-02-05 11:00:00 Czytaj oryginał (ang.)
4 Stocks That Sport Impressive Interest Coverage Ratio BMRN, CAKE, LDOS & ENSG's impressive interest coverage ratios highlight that these companies can withstand financial hardships. zacks.com 2025-02-04 12:11:33 Czytaj oryginał (ang.)
10 Magnificent Stocks That Can Make You Richer in 2025 For a second straight year, investors have been given every reason to smile. As of this writing, with one trading day left in 2024, the iconic Dow Jones Industrial Average, benchmark S&P 500, and growth stock-powered Nasdaq Composite have respectively gained 13%, 24%, and 30%! fool.com 2025-01-03 07:06:00 Czytaj oryginał (ang.)
3 Reasons Why Growth Investors Shouldn't Overlook BioMarin (BMRN) BioMarin (BMRN) is well positioned to outperform the market, as it exhibits above-average growth in financials. zacks.com 2025-01-02 15:54:34 Czytaj oryginał (ang.)
BMRN or TECH: Which Is the Better Value Stock Right Now? Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either BioMarin Pharmaceutical (BMRN) or Techne (TECH). But which of these two stocks presents investors with the better value opportunity right now? zacks.com 2025-01-02 14:46:39 Czytaj oryginał (ang.)
Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. zacks.com 2024-12-26 12:40:23 Czytaj oryginał (ang.)
Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. zacks.com 2024-12-24 12:45:29 Czytaj oryginał (ang.)
Is the Options Market Predicting a Spike in BioMarin Pharmaceutical (BMRN) Stock? Investors need to pay close attention to BioMarin Pharmaceutical (BMRN) stock based on the movements in the options market lately. zacks.com 2024-12-19 11:40:33 Czytaj oryginał (ang.)
BioMarin Pharmaceutical (BMRN) is a Top-Ranked Momentum Stock: Should You Buy? Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. zacks.com 2024-12-11 12:50:16 Czytaj oryginał (ang.)
Why Is BioMarin (BMRN) Down 1.9% Since Last Earnings Report? BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? zacks.com 2024-11-28 14:36:13 Czytaj oryginał (ang.)
Can BioMarin Stock Live Up to Wall Street's High Expectations? BioMarin Pharmaceutical NASDAQ: BMRN has been a rough investment for a long time. Over the past 10 years, shares have provided a total return of -28%. marketbeat.com 2024-11-22 09:01:17 Czytaj oryginał (ang.)
Biomarin: Challanges Mount, But Sale Rumours Make For A Risky "Buy" Call Biomarin has a near $3bn per annum rare disease drug franchise, and is profitable. Arguably the business is undervalued by the market. The company faces threats to key drugs in the indications of acondrophasia, hemophilia and patent expiry issues, making the medium term outlook tricky. Long term, a new management is promising $4bn of revenues by 2027, and long term mid-teen revenue growth. seekingalpha.com 2024-11-21 17:00:40 Czytaj oryginał (ang.)
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. zacks.com 2024-11-21 12:45:41 Czytaj oryginał (ang.)
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. zacks.com 2024-11-20 12:45:24 Czytaj oryginał (ang.)
BioMarin Presents Real-World Evidence Further Supporting Safety and Efficacy of VOXZOGO® (vosoritide) in Children with Achondroplasia at the European Society for Paediatric Endocrinology (ESPE) Meeting 2024 SAN RAFAEL, Calif. , Nov. 16, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced positive and consistent results from multiple real-world evidence studies of VOXZOGO® (vosoritide) in children with achondroplasia. prnewswire.com 2024-11-16 12:45:00 Czytaj oryginał (ang.)
BioMarin to Participate in Three Upcoming Investor Conferences UBS Global Healthcare Conference on November 12 at 11:00 am PST Jefferies London Healthcare Conference on November 19 at 9:00 am GMT 7th Annual Evercore ISI HealthCONx Conference on December 4 at 7:00 am PST SAN RAFAEL, Calif. , Nov. 6, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will present at three upcoming investor conferences. prnewswire.com 2024-11-06 10:00:00 Czytaj oryginał (ang.)
Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. zacks.com 2024-11-05 12:41:13 Czytaj oryginał (ang.)
Is BioMarin (BMRN) a Solid Growth Stock? 3 Reasons to Think "Yes" BioMarin (BMRN) is well positioned to outperform the market, as it exhibits above-average growth in financials. zacks.com 2024-11-04 15:46:11 Czytaj oryginał (ang.)
BioMarin (BMRN) Upgraded to Buy: Here's Why BioMarin (BMRN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. zacks.com 2024-11-04 15:01:15 Czytaj oryginał (ang.)
BMRN vs. INCY: Which Stock Is the Better Value Option? Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of BioMarin Pharmaceutical (BMRN) and Incyte (INCY). But which of these two companies is the best option for those looking for undervalued stocks? zacks.com 2024-11-04 14:46:23 Czytaj oryginał (ang.)
Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. zacks.com 2024-11-04 12:50:24 Czytaj oryginał (ang.)
BioMarin Q3 Earnings & Revenues Beat Estimates, '24 Guidance Raised BMRN reports better-than-expected third-quarter results, beating both earnings and sales estimates. Management raises 2024 guidance. zacks.com 2024-10-30 14:10:28 Czytaj oryginał (ang.)